Stay updated with breaking news from John Sims. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Eli Lilly and Co. is seeking Food and Drug Administration approval of donanemab. If cleared, it would be only the second Alzheimer's treatment convincingly shown to delay the mind-robbing disease.
Another experimental Alzheimer's drug can modestly slow patients' inevitable worsening — by about four to seven months, researchers reported Monday.
Another experimental Alzheimer’s drug can modestly slow patients’ inevitable worsening — by about four to seven months, researchers reported Monday.
Questions about whether donanemab - and two similar drugs from US pharma giants - are really the answer to combating the devastating disease remain unanswered.
But the drug, an antibody that attacks the sticky protein amyloid, does not work as well in people with more advanced disease. But the drug, an antibody that attacks the sticky protein amyloid, does not work as well in people with more advanced disease.